Cargando…

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F

Respiratory syncytial virus (RSV) continues to pose serious threats to pediatric populations due to the lack of a vaccine and effective antiviral drugs. RSV fusion (F) glycoprotein mediates viral-host membrane fusion and is a key target for neutralizing antibodies. We generated 23 full-human monoclo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Chunyan, Su, Caixia, Sun, Xiaoyu, Lu, Xiao, Si, Chuanya, Liu, Caixuan, Yang, Zhuo, Yuan, Hong, Huang, Yuying, Wen, Jing, He, Yonghui, Zhang, Yaguang, Ma, Liyan, Cong, Yao, Zhao, Gan, Ling, Zhiyang, Wang, Bin, Sun, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Science China Press 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971687/ https://www.ncbi.nlm.nih.gov/pubmed/36853487 http://dx.doi.org/10.1007/s11427-022-2250-0

Ejemplares similares

A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues
por: Yi, Chunyan, et al.
Publicado: (2022)

Transient opening of trimeric prefusion RSV F proteins
por: Gilman, Morgan S. A., et al.
Publicado: (2019)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
por: Tang, Aimin, et al.
Publicado: (2019)

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike
por: Huo, Jiandong, et al.
Publicado: (2020)

Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes
por: Xiao, Xiao, et al.
Publicado: (2019)

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
por: Gilman, Morgan S. A., et al.
Publicado: (2015)

Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
por: Yang, Yongping, et al.
Publicado: (2021)

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
por: Yi, Chunyan, et al.
Publicado: (2021)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody
por: Callaway, Heather M., et al.
Publicado: (2022)

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
por: Yi, Chunyan, et al.
Publicado: (2020)

Unique binding pattern for a lineage of human antibodies with broad reactivity against influenza A virus
por: Sun, Xiaoyu, et al.
Publicado: (2022)

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
por: Rigter, Alan, et al.
Publicado: (2013)

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
por: van der Fits, Leslie, et al.
Publicado: (2020)

Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
por: Lamichhane, Pramila, et al.
Publicado: (2022)

Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein
por: Hellert, Jan, et al.
Publicado: (2020)

A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein
por: White, Kris M., et al.
Publicado: (2014)

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
por: Lu, Mijia, et al.
Publicado: (2022)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

1644. A Potent Broadly Neutralizing Antibody Isolated From Human Memory B-cells Binding to Conserved Site IV on the RSV F Protein
por: Vora, Kalpit, et al.
Publicado: (2018)

Architecture of the SARS coronavirus prefusion spike
por: Beniac, Daniel R, et al.
Publicado: (2006)

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

Junctional and somatic hypermutation-induced CX(4)C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody
por: Yi, Chunyan, et al.
Publicado: (2020)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies
por: Jones, Harrison G., et al.
Publicado: (2018)

Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F
por: Harshbarger, Wayne, et al.
Publicado: (2020)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ol5pf3vq1j48pn2uojt6vrhsk8